Barrister Global Services Network Inc
Change company Symbol lookup
Select an option...
BRTR Barrister Global Services Network Inc
EBTC Enterprise Bancorp Inc
FSLY Fastly Inc
BNR Burning Rock Biotech Ltd
FCNKX Fidelity® Contrafund® Fund Class K
CAT Caterpillar Inc
POAGX PRIMECAP Odyssey Aggressive Growth Fund
VFIFX Vanguard Target Retirement 2050 Fund Investor Shares
CMCSA Comcast Corp
CUZ Cousins Properties Inc
Go

Company profile

Barrister Global Services Network, Inc. is a provider of provides multi-vendor information technology (IT) services. The Company serves customers in commercial, consumer, educational and Governmental markets through direct and indirect channels. The Company's services range from onsite break/fix hardware repair and per incident on-site hardware repair to managed help desk and equipment installations, de-installations and disposals. The Company supports its retail clients with point-of-sale (POS) and kiosk services ranging from deployment, to installation, to ongoing onsite maintenance and hot-swap services. The Company delivers full service maintenance covering both in-warranty and out-of-warranty multi-vendor equipment. Services include remedial maintenance, replacement parts and technical support. The Company offers full service maintenance for multi-vendor POS systems, such as on-site service and depot repair service.

Closing Price
--
Day's Change
--
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
4

UPDATE: Kodak's stock triples as company announces pandemic plan to start making pharmaceutical ingredients

8:29 am ET July 29, 2020 (MarketWatch)
Print

By Jaimy Lee

The pandemic has heightened longstanding worries about pharmaceutical ingredients sourced in countries like China and India that are used to make U.S. medicines

The Trump administration's $765 million loan to the Eastman Kodak Co. for its launch of a business making pharmaceutical ingredients sent shares of the iconic camera company soaring.

Kodak's stock (KODK) rallied more than 200% on Tuesday after the news was announced (http://www.marketwatch.com/story/kodaks-stock-nearly-triples-after-report-of-765-million-government-loan-to-help-produce-generic-drugs-2020-07-28) by the Trump administration. The company emerged from a 2011 bankruptcy in 2013, and its shares tumbled from a 10-year high of $37.20 on Jan. 9, 2014, to a low of $1.55 on March 23 of this year.

"Never again do we want to rely on shipments from China or elsewhere in order to get lifesaving medical supplies," New York Gov. Andrew Cuomo said in a statement.

Kodak, which is based in Rochester, N.Y., and has a long history of manufacturing chemicals used in photographic film, now plans to support "America's self-sufficiency in producing the key pharmaceutical ingredients we need to keep our citizens safe," Kodak's executive chairman, Jim Continenza, said in a statement.

See also:U.S. case tally climbs above 4.3 million as Texas becomes fourth state with more than 400,000 cases (http://www.marketwatch.com/story/coronavirus-update-us-case-tally-climbs-above-429-million-as-texas-becomes-fourth-state-with-more-than-400000-cases-2020-07-28)

The Trump administration said the Kodak deal is the first of its kind and uses powers afforded by the Defense Production Act. The administration previously used these powers (http://www.marketwatch.com/story/ford-partners-with-ge-3m-to-build-ventilators-covid-19-protective-equipment-2020-03-24) to demand that Ford Motor Co. (F) begin manufacturing respirators and masks and that General Motors Co. (GM) make ventilators.

It also awarded $354 million to Phlow Corp (https://www.prnewswire.com/news-releases/phlow-corporation-awarded-354-million-hhsasprbarda-contract-to-manufacture-essential-medicines-in-shortage-301061648.html?tc=eml_cleartime). in May to start producing active pharmaceutical ingredients, or API, among other chemical ingredients, used in certain essential medications. A spokesperson for Phlow said the company can't disclose the list of drugs, but it includes treatments for pain and blood pressure that can be used by hospitalized COVID-19 patients. The total contract is worth up to $812 million. Phlow cites a shift toward producing API in China and India as the rationale behind its business model.

But one Wall Street analyst is questioning why these contracts were not awarded to companies like Amneal Pharmaceuticals Inc. (AMRX), Mylan (MYL), and Teva Pharmaceutical Industries Ltd. (TEVA.TV), all of whom have generic-drug manufacturing know-how.

"We find it puzzling why generic pharmaceutical companies who have the capabilities and know-how for this have not yet been awarded such contracts," SVB Leerink's Ami Fadia told investors on Wednesday. "Bringing pharma manufacturing back to the U.S. is no easy feat and (we) continue to believe that leading generic manufacturers will eventually be part of the solution."

Drug makers largely do not manufacture API in the U.S., and many have instead turned to lower-cost countries like China and India to source some or all of their API.

Before the COVID-19 pandemic, there had been growing concern in the U.S. about where API were manufactured, driven in large part by generic-drug shortages and questions about the integrity and stability of the Chinese and Indian supply chains, especially as tensions with China have accelerated (http://www.marketwatch.com/story/pompeo-to-give-china-speech-as-tensions-with-us-flare-2020-07-23) during a U.S. election year.

Don't miss: Race for a COVID-19 vaccine has drug makers scaling up manufacturing -- before one is developed (http://www.marketwatch.com/story/race-for-a-covid-19-vaccine-has-drug-makers-scaling-up-manufacturing-before-one-is-developed-2020-06-25)

Only 28% of the manufacturing facilities making ingredients used in drugs sold in the U.S. were produced domestically, as of August 2019, according to the Food and Drug Administration. Most of the remaining facilities producing ingredients for American pharmaceuticals are in China (13%), the European Union (26%) and India (18%). However, when it comes to ingredients used in U.S. medicines deemed "essential" by the World Health Organization, U.S.-based facilities produce only 21% of those ingredients, while China produces 15%.

"The number of Chinese facilities producing APIs for the U.S. market has increased over the past decade, as part of a massive movement of pharmaceutical production offshore," FDA official Dr. Janet Woodcock testified (https://www.fda.gov/news-events/congressional-testimony/safeguarding-pharmaceutical-supply-chains-global-economy-10302019) before a House committee hearing last year. "This movement is being driven by the pharmaceutical industry's desire for cost savings and less stringent environmental regulations."

Sandoz, the generic-drugs business of the Swiss drug company Novartis (NOVN.EB), recently promoted the fact that less than 2% of its products have API that are single-sourced from China and India, a decision that "highlighted the strength of its supply chain," Fadia told investors in April. The company also signed a deal Monday with the Austrian government to manufacture API there, including ingredients to supply penicillin to Europe for the next decade, "despite fierce global price competition, particularly from China," it said.

But then came the pandemic. The coronavirus swept through China and other parts of Asia, shutting down factories and clinical trials and creating worry for drug makers and investors who are well aware of America's reliance on Chinese API producers.

The outbreaks of the virus in China presented "primary near-term business risks in the pharmaceutical sector, particularly with respect to the sourcing of active pharmaceutical ingredients and associated intermediates from countries at the epicenter of the crisis, mainly China," Raymond James analysts told investors in mid-March.

Read:Soaring demand for ventilators creates political tension, promises to ramp up manufacturing (http://www.marketwatch.com/story/soaring-demand-for-ventilators-creates-political-tension-promises-to-ramp-up-manufacturing-2020-03-25)

Premier Inc. (PINC), which provides group purchasing and other health-care data services, has advocated for stronger domestic manufacturing of API for more than 15 years. It applauded the Kodak news -- "announcements of this nature are a step in the right direction" -- but also noted the challenges in building out an API manufacturing process from scratch.

"Premier is hopeful that the U.S. also looks at how it can leverage existing API manufacturing capacity in the country to help create global diversification and stabilize the drug supply chain in a more expedited and cost effective manner," Soumi Saha, Premier's senior director of advocacy, said in a statement.

After Tuesday's 205% surge, Kodak's stock is up 72% for the year. The S&P 500 is down 0.4% in 2020.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 29, 2020 08:29 ET (12:29 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.